Funding for this research was provided by:
Centers for Disease Control and Prevention (U48DP001936, U48DP001934, U48DP0010909, U48DP001911, U48DP001903, U48DP001946, U48DP001949, U48DP001924, U48DP001944, U48DP001938)
National Cancer Institute (R25CA057712, R25CA116339, R01CA124397, R21CA136460)
Received: 7 September 2017
Accepted: 5 March 2018
First Online: 27 March 2018
Ethics approval and consent to participate
: All study procedures were approved by the Coordinating Center at the University of North Carolina at Chapel Hill, UNC Office of Human Research Ethics 12-1586. The Institutional Review Boards of each CPCRN also approved the study procedures (UCLA Office of the Human Research Protection Program, Colorado Multiple Institution Review Board, Emory University Institutional Review Board, Washington University Institutional Review Board, University of South Carolina Office of Research Compliance, University of Texas Health Science Center at Houston Committee for the Protection of Human Subjects, University of Washington Human Subjects Division).
: Not applicable.
: The authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.